Health Carerss

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

Tickers in this article: BIIB LLY JNJ ABBV ELN PFE

A TauRx Therapeutics drug designed to dissolve tangles of a protein called tau in the brain failed to slow cognitive and functional declines of Alzheimer's patients compared with a control.

07/27/16 - 08:00 AM EDT

Cerner Could Be a Prized Asset for IBM

Tickers in this article: CERN IBM GOOGL MCK MSFT VCRA

The health care IT firm is viewed as a 'crown jewel' but may still be too large of an asset for logical buyers to get comfortable with.

07/27/16 - 06:02 AM EDT

Wait for Another 10% Drop In Gilead Before Buying

Wait for Another 10% Drop In Gilead Before Buying

Tickers in this article: GILD

The stock is poised to test support at around $78 per share, or 10% lower. At that point, Gilead stock is safe to buy. Anything in between is trap.

07/26/16 - 06:17 AM EDT

Take Profits in PetMed, Then Wait for a Pullback

Take Profits in PetMed, Then Wait for a Pullback

Tickers in this article: PETS SPX VHT

At best, the stock should be priced at around $18, or 12% lower.

07/26/16 - 05:57 AM EDT

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Tickers in this article: RLYP ARDX SNY AGN MDVN ACAD

Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.

07/21/16 - 05:00 PM EDT

Valeant's Drug Approvals May Save the Day

Valeant's Drug Approvals May Save the Day

Tickers in this article: VRX JNJ

Valeant could rake in more than $1 billion annually in new sales after FDA approval of a key drug.

07/20/16 - 12:30 PM EDT

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Tickers in this article: CELG AGIO JUNO BLUE EPZM BMY

Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.

07/19/16 - 07:01 AM EDT

Biotech Stock Mailbag: Heron, Exelixis

Biotech Stock Mailbag: Heron, Exelixis

Tickers in this article: HRTX EXEL BMY

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

07/08/16 - 06:58 AM EDT

Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks

Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks

Tickers in this article: JUNO KITE NVS RHHBY AMGN

Juno Therapeutics reminds investors yet again that the business of biotech -- developing new medicines that are effective and reasonably safe -- is hard to get right.

07/08/16 - 06:50 AM EDT

Goldman Sachs Recommends These 14 Conviction Buy Stocks for the Rest of 2016

Goldman Sachs Recommends These 14 Conviction Buy Stocks for the Rest of 2016

Tickers in this article: AMZN DLTR LOW MHK TWX A

Goldman Sachs expects "rising uncertainty" in the second half of 2016 and suggests that investors stick to stocks within defensive sectors including consumer, health care and telecom services.

07/07/16 - 06:58 AM EDT

XBiotech Cancer Drug Survival Claim Falls Apart Under Scrutiny

XBiotech Cancer Drug Survival Claim Falls Apart Under Scrutiny

Tickers in this article: XBIT GTXI

If the messy, confused clinical data disclosed Saturday by XBiotech are any indication, an approval in Europe for its colon cancer drug is far from a sure thing.

07/05/16 - 08:35 AM EDT

The 10 Worst-Performing S&P 500 Stocks in June

The 10 Worst-Performing S&P 500 Stocks in June

Tickers in this article: LNC ETFC DAL BIIB ALXN SIG

Brexit volatility put a major damper on the global markets this month, and investors who owned these 10 S&P 500 stocks saw their profits shrink substantially in June.

07/02/16 - 12:40 PM EDT

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Tickers in this article: LLY BLUE IBB XBI AMGN CELG

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

07/01/16 - 07:01 AM EDT

Teva Inches Closer to Completion of Allergan Generics Deal

Teva Inches Closer to Completion of Allergan Generics Deal

Tickers in this article: TEVA AGN IPXL

Australia's Mayne will shell out $652 million for a basket of generics products from Teva as the latter works to complete its pending Allergan generics purchase.

06/28/16 - 05:35 PM EDT